Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. (Q53674199)

17 May 2018

title

Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. (English)

1 reference

17 May 2018

main subject

mucopolysaccharidosis VI

1 reference

4

Joleen White

1 reference

17 May 2018

John Hopwood

9

object named as

John J Hopwood

1 reference

17 May 2018

author name string

Dyane Auclair

1

1 reference

17 May 2018

John Finnie

2

1 reference

17 May 2018

Steven U Walkley

3

1 reference

17 May 2018

Timothy Nielsen

5

1 reference

17 May 2018

Maria Fuller

6

1 reference

17 May 2018

Alphonsus Cheng

7

1 reference

17 May 2018

Charles A O'Neill

8

1 reference

17 May 2018

language of work or name

English

0 references

publication date

1 January 2012

1 reference

17 May 2018

published in

Pediatric Research

1 reference

17 May 2018

volume

71

1 reference

17 May 2018

issue

1

1 reference

17 May 2018

page(s)

39-45

1 reference

17 May 2018

https://scigraph.springernature.com/pub.10.1038/pr.2011.13

exact match

0 references

cites work

Myelography Features of Mucopolysaccharidoses: A New Sign

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Compressive myelopathy associated with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Magnetic resonance imaging in the diagnosis of the cranio-cervical manifestations of the mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Human dural thickness measured by ultrasonographic method: reflection of intracranial pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Small animal imaging facility: new perspectives for the radiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Mechanical properties of dura mater from the rat brain and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPR.2011.13

31 March 2020

Identifiers

DOI

10.1038/PR.2011.13

1 reference

17 May 2018

1 reference

17 May 2018